92.5 A+
Bremelanotide
Also known as: PT-141, Vyleesi
FDA Approved Unregulated — Sold as research chemical
Research Evidence 90.0/100
Safety Profile 95.0/100
10 Clinical Trials
PHASE4: 2 PHASE3: 3 PHASE2: 4 PHASE1: 1
- Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk PHASE4 COMPLETED Cosette Pharmaceuticals, Inc.
- Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder PHASE4 COMPLETED Imperial College Healthcare NHS Trust
- A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) PHASE3 COMPLETED Kwang Dong Pharmaceutical co., ltd.
- 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder PHASE3 COMPLETED Palatin Technologies, Inc
- 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder PHASE3 COMPLETED Palatin Technologies, Inc
Showing 5 of 10 trials.
20 Research Papers
- Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer. J Minim Invasive Gynecol unknown
- Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies. Expert Rev Clin Pharmacol Review
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. J Minim Invasive Gynecol Review
- 2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns. Support Care Cancer Review
- A biodegradable suction patch for sustainable transbuccal peptide delivery. J Control Release unknown
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
Bremelanotide has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Bremelanotide FDA approved?
No, Bremelanotide has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Bremelanotide been studied in?
Bremelanotide has been studied in 10 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Bremelanotide?
Bremelanotide has a CheckPeptides trust score of 92.5/100 (grade: A+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- Melanocortin receptor agonist
- Molecular Weight
- 1025.2 Da
- PubChem
- CID 9941379 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 95.0/100
Evidence Summary
- Clinical Trials
- 10
- Research Papers
- 20
- Trust Score
- 92.5/100
- Grade
- A+